Cartesian Therapeutics RNAC
NASDAQ RNAC
$9.15 +0.03 (+0.33%)
As of: Sep 4, 2026 · 2:53 PM EDT

Cartesian Therapeutics (RNAC) Non Operating Interest Expenses (2015 - 2026)

Analysis

Cartesian Therapeutics (RNAC) Non Operating Interest Expenses (2015 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.58 Bn 130.73 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.33 Bn 77.33 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.43 Bn 58.24 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.84 Bn 52.70 Bn 52.00 Mn -
5 Revolution Medicines 44.01 Bn 44.01 Bn - 23.78 Mn
6 BeOne Medicines 39.93 Bn 34.83 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.47 Bn 32.16 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.39 Bn 27.56 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Cartesian Therapeutics 269.62 Mn 269.62 Mn - 852,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 852,000.00
Sep 30, 2023 1.27 Mn
Jun 30, 2023 752,000.00
Mar 31, 2023 808,000.00
Dec 31, 2022 807,000.00
Sep 30, 2022 802,000.00
Jun 30, 2022 715,000.00
Mar 31, 2022 707,000.00
Dec 31, 2021 711,000.00
Sep 30, 2021 711,000.00
Jun 30, 2021 711,000.00
Mar 31, 2021 711,000.00
Dec 31, 2020 713,000.00
Sep 30, 2020 365,000.00
Jun 30, 2020 205,000.00
Mar 31, 2020 273,000.00
Dec 31, 2019 335,000.00
Sep 30, 2019 388,000.00
Jun 30, 2019 400,000.00
Mar 31, 2019 396,000.00